文献速递精神分裂症与精神病性障碍

氯氮平治疗与COVID-19感染风险的回顾性队列研究

Clozapine treatment and risk of COVID-19 infection: retrospective cohort study.
PubMed 文献 · Br J Psychiatry · 2021-01-01

该研究利用英国伦敦南部与莫兹利NHS基金会临床记录,纳入6309例精神分裂症谱系障碍且正在服用抗精神病药的患者,比较氯氮平与其他抗精神病药在2020年3月1日至5月18日期间感染COVID-19的风险。结果显示,氯氮平组感染风险升高(未调整HR=2.62,95%CI 1.73-3.96),调整混杂因素后仍升高(调整HR=1.76,95%CI 1.14-2.72)。

要点

  • 氯氮平治疗者COVID-19感染风险高于其他抗精神病药治疗者。
  • 未调整HR=2.62(95%CI 1.73-3.96),调整后HR=1.76(95%CI 1.14-2.72)。
  • 需在其他样本中进一步验证该关联。

核心结论

  • 氯氮平治疗与精神分裂症谱系障碍患者COVID-19感染风险增加相关。
  • 该关联在调整性别、年龄、族裔、BMI、吸烟状态及服务使用后仍存在。
  • 作者认为需在其他样本中进一步研究以确认该关联。

研究设计与样本

  • 回顾性队列研究,数据来自South London and Maudsley NHS Foundation Trust临床记录。
  • 纳入6309例ICD-10诊断精神分裂症谱系障碍且正在服用抗精神病药者。
  • 比较氯氮平与其他抗精神病药治疗者在2020年3月1日至5月18日期间的COVID-19感染风险。

主要发现

  • 6309例中102例COVID-19检测阳性。
  • 氯氮平组较其他抗精神病药组感染风险升高,未调整HR=2.62(95%CI 1.73-3.96)。
  • 调整潜在混杂因素(含临床接触)后HR=1.76(95%CI 1.14-2.72)。

关键数值与推荐

  • 未调整风险比HR=2.62,95%CI 1.73-3.96。
  • 调整后风险比HR=1.76,95%CI 1.14-2.72。
  • 调整因素包括性别、年龄、族裔、BMI、吸烟状态和SLAM服务使用。

临床怎么用

  • 对接受氯氮平治疗的精神分裂症谱系障碍患者,应关注其COVID-19感染风险。
  • 原文讨论潜在临床意义,但未给出具体干预推荐。

局限性

  • 作者指出需在其他样本中进一步研究以确认该关联。
  • 原文未报告其他局限性细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clozapine, an antipsychotic with unique efficacy in treatment-resistant psychosis, is associated with increased susceptibility to infection, including pneumonia. AIMS: To investigate associations between clozapine treatment and increased risk of COVID-19 infection in patients with schizophrenia-spectrum disorders who are receiving antipsychotic medications in a geographically defined population in London, UK. METHOD: Using information from South London and Maudsley NHS Foundation Trust (SLAM) clinical records, via the Clinical Record Interactive Search system, we identified 6309 individuals who had an ICD-10 diagnosis of schizophrenia-spectrum disorders and were taking antipsychotics at the time of the COVID-19 pandemic onset in the UK. People who were on clozapine treatment were compared with those on any other antipsychotic treatment for risk of contracting COVID-19 between 1 March and 18 May 2020. We tested associations between clozapine treatment and COVID-19 infection, adjusting for gender, age, ethnicity, body mass index (BMI), smoking status and SLAM service use. RESULTS: Of 6309 participants, 102 tested positive for COVID-19. Individuals who were on clozapine had increased risk of COVID-19 infection compared with those who were on other antipsychotic medication (unadjusted hazard ratio HR = 2.62, 95% CI 1.73-3.96), which was attenuated after adjusting for potential confounders, including clinical contact (adjusted HR = 1.76, 95% CI 1.14-2.72). CONCLUSIONS: These findings provide support for the hypothesis that clozapine treatment is associated with an increased risk of COVID-19 infection. Further research will be needed in other samples to confirm this association. Potential clinical implications are discussed.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Govind R, Fonseca de Freitas D, Pritchard M, et al. Clozapine treatment and risk of COVID-19 infection: retrospective cohort study. Br J Psychiatry. 2021. PMID: 32713374. doi:10.1192/bjp.2020.151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。